The Latest Breaking News from NICE

The injection is recommended as an additional maintenance treatment for patients over 12 when usual medications have not proven effective enough

The U.K.’s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc’s (NASDAQ:AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

‘The biggest thing it offers is hope,’ says patient involved in clinical trial which cured cancer in significant portion of leukaemia sufferers

Researchers found benefits including reduced blood pressure were reversed after patients ceased taking the jab

About 1,500 patients in England and Wales live with the rare heart condition

Exclusive: Clinical guidelines should change to avoid exposing young people to potentially harmful side-effects, researchers say

The technology will be used to spot early signs of bowel cancer

Many people around the world have made investments in artificial intelligence stocks over the last year. When a member of Congress buys shares of a $7 billion AI-related company, investors likely take notice.

NICE Ltd (NASDAQ:NICE) shares rose Thursday after the company reported its third-quarter results, beating street estimates.

These firms present at least a modest risk/reward profile, but could be preparing for a share price turnaround depending upon how earnings season plays out.

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’